Endocrinology

Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.

Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.

An analysis of data from type 1 diabetes prevention trials is shedding new light on factors associated with increased and decreased likelihood of screening for type 1 diabetes among participants considered eligible for each trial.

Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.

A systematic review and meta-analysis of observational studies of people with diabetes suggest more than 1-in-4 also had a diagnosis of osteoporosis.

MAFLD-lean and MAFLD-diabetes subgroups recorded a higher risk of all-cause and disease-specific mortality compared to the MAFLD-overweight/obese group.

A patient in their mid-50s with a history of diabetes who had already been on antibiotics for 4 days for cellulitis diagnosed in your emergency department, but had not improved, and then, yesterday, noticed an ankle wound. What additional testing should be considered for this patient?

To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.

Our editorial team is celebrating the end of 2022 by recapping our most popular content related to diabetes technology from the past year.

To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.

Our editorial team is kicking off the final week of the year by recapping our the most talked about approvals and clearances related to diabetes management from the US Food and Drug Administration in 2022, including tirzepatide, teplizumab, Dexcom G7, and more!

The last full weekend of each month, our editorial team compiles a list of our most popular endocrinology content from the past month for a month in review recap. The December 2022 endocrinology month in review features coverage of the FDA’s clearance of Dexcom G7, new data related to use of SGLT2 inhibitors in pediatric type 2 diabetes, and the ADA's Standards of Care in Diabetes—2023.

In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.

A systematic review and meta-analysis of studies reporting the pooled prevalence of obesity in pediatric type 2 diabetes suggest 75% of these patients had obesity.

Reflections on a century's worth of developments toward a major breakthrough in T1D this year.

In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.

Beginning January 1, 2023, all new content and insights from the editorial teams of Endocrinology Network, Practical Cardiology and Rheumatology Network will be hosted on HCPLive.Com.

On December 8, Dexcom announced their Dexcom G7 CGM system had received US FDA clearance for use in people with all types of diabetes aged 2 years and older.

The Endocrine Society has released updated guidance for management of hypoglycemia in people with diabetes, which represents their first guidance on the topic since 2009 and places a new emphasis on the role of diabetes technology, insulin analogs, and glucagon use.

Data from the BAPO trial suggests use of oral butyrate supplementation was associated with a 40% absolute increase in rate of the trial's BMI-based primary outcome at 6 months relative to placebo therapy in a population of pediatric patients with obesity.

Our latest endocrine case report features a woman in her 40s with a history of diabetes mellitus presenting with flu-like illness with multiple symptoms. Can you determine the correct diagnosis?

Gregory Weiss, MD, provides perspective on how improved safety of these procedures has revolutionized the way clinicians view use of bariatric and metabolic surgeries as a method for inducing weight loss in people with overweight and obesity.

An analysis of survey data from more than 1400 adults in the UK provides insight into potential risk factors for developing long COVID symptoms, with results indicating both female sex and increased body mass index as potential risk factors.

Results of the DIRECT-PLUS trial provide clinicians with new insights into the impact of the Mediterranean diet and a modified Mediterranean diet as a method for inducing weight loss.

The November 2022 endocrine month in review features coverage of the FDA’s approval of teplizumab, new data related to use of GLP-1 receptor agonists, and a trio of stories on topics pertaining to diabetes technology.

A Johns Hopkins-led analysis provides a snapshot of trends in racial disparities seen in both uptake of and engagement in discussions with providers around continuous glucose monitoring and insulin pumps among adults with type 1 diabetes.